null
100% Quality Guarantee
PhD-Level Technical Support
Key Features

Anti-KCNQ1 Antibody [N37A/10 (Formerly sold as S37A-10)]

SKU STMA00085
Antibody Type Monoclonal
Applications WB
Applications IHC
Applications ICC/IF
Applications IP
Applications AM
Reactivity Human
Reactivity Mouse
Reactivity Rat
Reactivity Hamster
Host Species Mouse
Isotype IgG1
€647
Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

KCNQ1 Antibody [N37A/10 (Formerly sold as S37A-10)]

KCNQ1 Antibody [N37A/10 (Formerly sold as S37A-10)] is a mouse monoclonal antibody directed against KCNQ1, offered by Assay Genie for research applications. Reported applications include WB, IHC, ICC/IF, IP and AM. Reported reactivity: Human, Mouse, Rat and Hamster. Supplied as IgG1, purified by Protein G.

KCNQ1 encodes the Kv7.1 potassium channel, a voltage-gated protein best known for its role in cardiac electrophysiology. In cardiac myocytes, Kv7.1 mediates the slow delayed rectifier potassium current (IKs), which is essential for repolarization and termination of the cardiac action potential. However, its expression in non-cardiac tissues, including inner ear neurons and select brain regions, suggests broader physiological relevance. Recent research has begun to uncover Kv7.1’s potential role in the nervous system, particularly in regulating neuronal excitability and maintaining ionic homeostasis. Potassium channels like Kv7.1 are critical for shaping action potentials, modulating synaptic transmission, and protecting neurons from hyperexcitability and excitotoxicity—key features implicated in neurodegenerative disease progression. Although less studied than other Kv7 family members in the brain, KCNQ1’s presence in neural tissue raises important questions about its contribution to auditory processing, neurodevelopment, and neurodegeneration. Dysregulation of potassium channel activity has been linked to disorders such as epilepsy, Alzheimer’s disease, and Parkinson’s disease, where altered ion channel function disrupts neural signaling and accelerates neuronal loss. As neuroscience research expands its focus on ion channelopathies, KCNQ1 is emerging as a candidate for further investigation. Understanding its role in neural circuits may reveal novel therapeutic strategies for restoring electrical balance and preventing neurodegenerative decline. This antibody is also available conjugated to ATTO 390, ATTO 488, ATTO 594, APC, Biotin, FITC, HRP, PerCP and RPE. Supplied in 100 µg. For research use only; not for diagnostic or therapeutic procedures.

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose